Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Lynda Foltz,Gian-Matteo Pica,Hacene Zerazhi,Jan Van Droogenbroeck,Sorin Visanica,Enrique Báez De La Fuente,Brian Leber,Antonio Medina De Almeida,Dana Ranta,Mauricio Reyes Cartes,Jean-Jacques Kiladjian,Linda Chrit,Zhaoyu Yin,Juliane Morando,Timothy Devos

doi:10.1182/blood-2018-99-111479

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Lynda Foltz, Gian-Matteo Pica + Show 13 more

Open Access

https://doi.org/10.1182/blood-2018-99-111479

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 3

Affiliation: University of British Columbia, Centre Hospitalier Métropole Savoie, AZ Sint-Jan, McMaster University, Centre Hospitalier Universitaire de Nancy, Délégation Paris 7, Hôpital Saint-Louis, Université Paris Cité, Novartis (Switzerland), KU Leuven

#Hematocrit Control #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Full Text